Amgen (AMGN) closed at $465.23 on November 10, 2026, unchanged from the previous close, on volume of 1,668,388 shares (30-day average 2,799,646).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 27, 2026 | Calendar Call Spread | 20-Nov-26 : 19-Mar-27 310 C | 4,390 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
PRNewswire (Mon, 9-Nov 4:00 PM ET)
Amgen (AMGN) Gets a Buy from Piper Sandler
TipRanks (Mon, 9-Nov 8:07 AM ET)
TipRanks (Mon, 9-Nov 6:10 AM ET)
Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
Seeking Alpha News (Sat, 7-Nov 11:36 AM ET)
Democratic lawmakers seen probing Trump drug pricing deals come January
Seeking Alpha News (Fri, 6-Nov 12:13 PM ET)
REPATHA LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY
PRNewswire (Thu, 5-Nov 9:00 AM ET)
Amgen Q3 2026 results highlight 17 products annualizing above $1 billion as operating margin expands
Market Chameleon (Wed, 4-Nov 2:25 AM ET)
AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
PRNewswire (Tue, 3-Nov 4:01 PM ET)
Amgen Sets Nov. 3 Webcast for Q3 2026 Results, With a 90-Day Replay Window
Market Chameleon (Thu, 29-Oct 4:02 AM ET)
AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS
PRNewswire (Wed, 28-Oct 4:30 PM ET)
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Amgen trades on the NASDAQ stock market under the symbol AMGN.
As of November 10, 2026, AMGN stock price was flat at $465.23 with 1,668,388 million shares trading.
AMGN has a beta of 0.15, meaning it tends to be less sensitive to market movements. AMGN has a correlation of 0.00 to the broad based SPY ETF.
AMGN has a market cap of $251.52 billion. This is considered a Mega Cap stock.
Last quarter Amgen reported $10 billion in Revenue and $6.45 earnings per share. This beat revenue expectation by $321 million and exceeded earnings estimates by $.68.
In the last 3 years, AMGN traded as high as $483.99 and as low as $253.30.
The top ETF exchange traded funds that AMGN belongs to (by Net Assets): VTI, VOO, QQQ, SCHD, IVV.
AMGN has outperformed the market in the last year with a price return of +48.4% while the SPY ETF gained +12.9%. AMGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +13.8% and +4.6%, respectively, while the SPY returned -2.8% and -2.0%, respectively.
AMGN support price is $455.68 and resistance is $474.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMGN shares will trade within this expected range on the day.
